Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
A phase 1b study of the ERK inhibitor MK-8353 plus pembrolizumab in patients with advanced solid tumors.
Journal: Investigational new drugs
Published: May 28, 2024
A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors.
Journal: Investigational new drugs
Published: December 20, 2023
Results of an open-label phase 1b study of the ERK inhibitor MK-8353 plus the MEK inhibitor selumetinib in patients with advanced or metastatic solid tumors.
Journal: Investigational new drugs
Published: December 22, 2022
Murine double minute 2 inhibition alone or with cytarabine in acute myeloid leukemia: Results from an idasanutlin phase 1/1b study⋆.
Journal: Leukemia research
Published: August 19, 2020
Phase 1 study of the MDM2 antagonist RO6839921 in patients with acute myeloid leukemia.
Journal: Investigational new drugs
Published: January 02, 2020
A phase 1 study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, in patients with advanced solid tumors.
Journal: Investigational new drugs
Published: September 23, 2019
A single-center, open-label study investigating the excretion balance, pharmacokinetics, metabolism, and absolute bioavailability of a single oral dose of [14C]-labeled idasanutlin and an intravenous tracer dose of [13C]-labeled idasanutlin in a single cohort of patients with solid tumors.
Journal: Cancer chemotherapy and pharmacology
Published: November 08, 2018
Phase 1 summary of plasma concentration-QTc analysis for idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors and AML.
Journal: Cancer chemotherapy and pharmacology
Published: December 24, 2017
Effects of posaconazole (a strong CYP3A4 inhibitor), two new tablet formulations, and food on the pharmacokinetics of idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors.
Journal: Cancer chemotherapy and pharmacology
Published: December 22, 2017
Acute myeloid leukemia patients' clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts.
Journal: Haematologica
Published: February 13, 2016
MDM2 antagonist clinical response association with a gene expression signature in acute myeloid leukaemia.
Journal: British journal of haematology
Published: April 10, 2015
Showing 1-11 of 11
Last Updated: 09/26/2026